Clinical Case Reports (Feb 2023)

Linear IgA bullous dermatosis and elevated bullous interleukin‐6 levels: Responsive to treatment with Anti‐IL‐6 receptor monoclonals

  • Stanley C. Jordan,
  • Bonnie Balzer,
  • Cynthia Nast,
  • Janet Atienza,
  • Katherine Lim,
  • Sanjeev Kumar,
  • Nicholas Nissen,
  • Bongha Shin

DOI
https://doi.org/10.1002/ccr3.6998
Journal volume & issue
Vol. 11, no. 2
pp. n/a – n/a

Abstract

Read online

Abstract Linear IgA bullous dermatosis (LABD) is a rare autoimmune/inflammatory skin condition. Here, we report on a patient who developed treatment resistant LABD. At diagnosis, elevations of IL‐6 and C‐reactive protein in the blood and extreme elevations of IL‐6 in LABD bullous fluid were seen. The patient responded well to tocilizumab (anti‐IL‐6 receptor) treatment.

Keywords